Statins may slow human aging by protecting against telomere shortening: A feature of senescent cells

Not only do statins extend lives by lowering cholesterol levels and reducing the risks of cardiovascular disease, but new research in the September 2013 issue of The FASEB Journal suggests that they may extend lifespans as well. Specifically, statins may reduce the rate at which telomeres shorten, a key factor in the natural aging process. This opens the door for using statins, or derivatives of statins, as an anti-aging therapy.

"By telomerase activation, statins may represent a new molecular switch able to slow down in our tissues and be able to lead healthy lifespan extension," said Giuseppe Paolisso, M.D., Ph.D., a researcher involved in the work from the Department of Internal Medicine, Surgical, Neurological Metabolic Disease and Geriatric Medicine at Second University of Naples in Naples, Italy.

To make this discovery, Paolisso and colleagues worked with two groups of subjects. The first group was under chronic statin therapy, and the second group (control), did not use statins. When researchers measured telomerase activity in both groups, those undergoing statin treatment had higher telomerase activity in their , which was associated with lower telomeres shortening along with aging as compared to the control group. This strongly highlights the role of telomerase activation in preventing the excessive accumulation of short telomeres.

"The great thing about statins is that they reduce risks for cardiovascular disease significantly and are generally safe for most people. The bad thing is that statins do have side effects, like muscle injury," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "But if it is confirmed that statins might actually slow aging itself—and not just the symptoms of aging—then statins are much more powerful drugs than we ever thought."

More information: Virginia Boccardi, Michelangela Barbieri, Maria Rosaria Rizzo, Raffaele Marfella, Antonietta Esposito, Luigi Marano, and Giuseppe Paolisso. A new pleiotropic effect of statins in elderly: modulation of telomerase activity. FASEB J September 2013 27:3879-3885, DOI: 10.1096/fj.13-232066

add to favorites email to friend print save as pdf

Related Stories

Should everyone over 65 take a statin?

Aug 28, 2013

(HealthDay)—Men and women over 65 who are at risk for cardiovascular disease but don't have any known heart problems might benefit from cholesterol-lowering drugs, a new study suggests.

Recommended for you

Barriers preventing post-stroke care

Jul 24, 2014

For stroke victims, rehabilitation is crucial to their recovery. But a Flinders University study conducted in Singapore found that rehabilitation rates following discharge from hospital are poor because of gaps in the continuum ...

Home-based rehabilitation for CVD patients

Jul 24, 2014

Patients who are found to suffer from cardiovascular diseases often have long years of treatment ahead of them and are urged to drastically change their lifestyle. But what is probably the most difficult ...

New remote patient monitoring devices available

Jul 24, 2014

(HealthDay)—Several new remote patient monitoring devices with useful applications are available or under development, according to an article published July 8 in Medical Economics.

User comments